Fusion Pharmaceuticals Inc. has officially filed a Form S-1 registration statement with the Securities and Exchange Commission (SEC) for an initial public offering of its common shares with pricing to be determined. The company listed US $100 million as the proposed maximum aggregate offering for the purpose of calculating filing fees.

Fusion Pharmaceuticals had previously filed a confidential draft registration statement with SEC on April 3, 2020.

Fusion Pharmaceuticals has applied to list its common shares on The Nasdaq Global Market under the symbol “FUSN.”

Hamilton, Ontario based Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Its Targeted Alpha Therapies, or TAT, platform together with its proprietary Fast-Clear linker technology enable the company to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha particle payloads to tumors.

Read the full story at privatecapitaljournal.com.